Search results for

In its outlook for the UPC, the preparatory committee casually breezes over some of the remaining thorny issues, including the London central division seat

The US patent law is about to undergo a major change with a raft of reforms set to be implemented. These changes are considered to be the most comprehensive since Congress passed the 1952 patent Act. But, the path has not been smooth, with voices of dissent materializing as the government carves out its plans. MIP and Oblon, Spivak, McClelland, Maier & Neustadt jointly hosted a roundtable discussion – at a real roundtable – in Washington DC in late summer, to discuss some of those concerns and what really needs to be done

Lin Li, Yujie Jin and Yali Shao of Liu Shen & Associates address the requirements AI inventions must meet in order to be protected under patent, trade secret and copyright law

The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules

The Supreme Court yesterday simultaneously granted cert and vacated the Federal Circuit’s decision in Eisai v Teva Pharmaceuticals USA, remanding it back to the appeals court to dismiss the case as moot

No big IP-related announcements came out of the Asia-Pacific Economic Cooperation (APEC) summit in Beijing. Should businesses be worried?

An owner of a standard-essential patent (SEP) who has committed to license on FRAND terms abuses its dominant position by seeking an injunction when the alleged infringer is willing to take a licence

Roberta Arantes of Daniel Law looks at how the Brazilian legal landscape has responded to shifts in the concept of branding and its related levels of protection

Managing IP reveals Patent Trial and Appeal Board filing figures for September and the third quarter, as well as ranking the top petitioners and patent owners for the first nine months of 2016. More PGRs than CBMs were filed for the first time ever in September

In the first of a series of interviews with in-house counsel, Managing IP spoke to Eric Notegen, head of the global patent function at F Hoffmann-La Roche, about his long career at the company, patent reform in the US and the future of the pharmaceutical industry worldwide. By Eklavya Gupte